Eric E. Hedrick
Impact in
- Genetics top 0.2%
- Chronic Lymphocytic Leukemia Research
- Pathology and Forensic Medicine top 0.2%
- Lymphoma Diagnosis and Treatment
Papers in
- Genetics 15
- Chronic Lymphocytic Leukemia Research 15
-
- Lymphoma Diagnosis and Treatment 14
- Co-authors
- Daniel J. Sargent (3 shared papers)Axel F. Grothey (3 shared papers)Mary M. Sugrue (2 shared papers)David M. Purdie (1 shared paper)Wei Dong (1 shared paper)Mark F. Kozloff (1 shared paper)Jeff Porter Sharman (5 shared papers)Richard R. Furman (2 shared papers)
- Journals
- Blood (13 papers)Journal of Clinical Oncology (5 papers)Hematological Oncology (2 papers)Leukemia (1 paper)Seminars in Oncology (1 paper)
- Partner nations
- United StatesChinaAustralia
In The Last Decade
Eric E. Hedrick
31 papers receiving 6.3k citations
Eric E. Hedrick's Hit Papers
Peers
Comparison fields: 5 of 103
- Genetics 3.0k
- Pathology and Forensic Medicine 3.0k
- Hematology 1.0k
- Oncology 2.1k
- Immunology 1.1k
Countries citing papers authored by Eric E. Hedrick
This map shows the geographic impact of Eric E. Hedrick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric E. Hedrick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric E. Hedrick more than expected).
Fields of papers citing papers by Eric E. Hedrick
This network shows the impact of papers produced by Eric E. Hedrick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric E. Hedrick. The network helps show where Eric E. Hedrick may publish in the future.
Co-authors
The 25 scholars most cited alongside Eric E. Hedrick, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 31 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia Hit paper breakdown → | 2013 | 1942 |
| 2 | Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies Hit paper breakdown → | 2012 | 957 |
| 3 | 2008 | 563 | |
| 4 | Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study Hit paper breakdown → | 2018 | 512 |
| 5 | 2008 | 503 | |
| 6 | The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia Hit paper breakdown → | 2018 | 368 |
| 7 | 2001 | 356 | |
| 8 | 1999 | 263 | |
| 9 | 2008 | 155 | |
| 10 | 2002 | 154 | |
| 11 | 2003 | 125 | |
| 12 | 2000 | 108 | |
| 13 | 2015 | 105 | |
| 14 | 2001 | 61 | |
| 15 | 2022 | 53 | |
| 16 | 2011 | 49 | |
| 17 | 2014 | 37 | |
| 18 | 2011 | 34 | |
| 19 | 2016 | 32 | |
| 20 | 2015 | 31 |
About Eric E. Hedrick
Eric E. Hedrick is a scholar working on Genetics, Pathology and Forensic Medicine, Oncology, Hematology and Molecular Biology, having authored 31 papers that have together received 6.5k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (15 papers), Lymphoma Diagnosis and Treatment (14 papers), Viral-associated cancers and disorders (5 papers), Colorectal Cancer Treatments and Studies (4 papers), Acute Myeloid Leukemia Research (3 papers), Cancer-related gene regulation (3 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Chronic Myeloid Leukemia Treatments (2 papers). The work is most often cited by research in Genetics (3.0k citations), Pathology and Forensic Medicine (3.0k citations), Hematology (1.0k citations), Oncology (2.1k citations) and Immunology (1.1k citations). Eric E. Hedrick has collaborated with scholars based in United States, China and Australia. Frequent co-authors include Daniel J. Sargent, Axel F. Grothey, Mary M. Sugrue, David M. Purdie, Wei Dong, Mark F. Kozloff, Jeff Porter Sharman, Richard R. Furman, Ranjana H. Advani and Sara Castaño Rodríguez. Their work appears in journals such as Blood, Journal of Clinical Oncology, Hematological Oncology, Leukemia and Seminars in Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.